Detalhe da pesquisa
1.
Perioperative and oncologic outcomes of laparoscopic versus open liver resection for combined hepatocellular-cholangiocarcinoma: a propensity score matching analysis.
Surg Endosc
; 37(2): 967-976, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36076103
2.
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.
Mol Cancer
; 21(1): 57, 2022 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35189910
3.
CircRNA UBAP2 serves as a sponge of miR-1294 to increase tumorigenesis in hepatocellular carcinoma through regulating c-Myc expression.
Carcinogenesis
; 42(10): 1293-1303, 2021 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34314478
4.
Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?
Hepatobiliary Pancreat Dis Int
; 20(1): 13-20, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33160852
5.
Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma.
Mol Cancer
; 19(1): 110, 2020 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32593303
6.
Predicting overall survival of patients with hepatocellular carcinoma using a three-category method based on DNA methylation and machine learning.
J Cell Mol Med
; 23(5): 3369-3374, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30784182
7.
The long noncoding RNA NORAD enhances the TGF-ß pathway to promote hepatocellular carcinoma progression by targeting miR-202-5p.
J Cell Physiol
; 234(7): 12051-12060, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30537113
8.
Circular RNA circTRIM33-12 acts as the sponge of MicroRNA-191 to suppress hepatocellular carcinoma progression.
Mol Cancer
; 18(1): 105, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31153371
9.
Lymphoid-specific helicase promotes the growth and invasion of hepatocellular carcinoma by transcriptional regulation of centromere protein F expression.
Cancer Sci
; 110(7): 2133-2144, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31066149
10.
Corrigendum to: "PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma" [J Hepatol 77 (2022) 163-176].
J Hepatol
; 78(4): 881-882, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564318
11.
Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
Hepatology
; 62(6): 1804-16, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26340507
12.
Ubiquitin-specific protease 7 accelerates p14(ARF) degradation by deubiquitinating thyroid hormone receptor-interacting protein 12 and promotes hepatocellular carcinoma progression.
Hepatology
; 61(5): 1603-14, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25557975
13.
Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications.
Tumour Biol
; 36(3): 1781-9, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25391422
14.
Role of 5-hydroxymethylcytosine level in diagnosis and prognosis prediction of intrahepatic cholangiocarcinoma.
Tumour Biol
; 36(4): 2763-71, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25480415
15.
Perioperative complication incidence and risk factors for retroperitoneal neuroblastoma in children: analysis of 571 patients.
World J Pediatr
; 20(3): 250-258, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38070095
16.
Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy.
Cell Rep
; 43(3): 113877, 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38421869
17.
Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma.
Nat Commun
; 15(1): 621, 2024 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38245530
18.
WDR4/TRIM28 is a novel molecular target linked to lenvatinib resistance that helps retain the stem characteristics in hepatocellular carcinomas.
Cancer Lett
; 568: 216259, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37279851
19.
Oncogenic miR-93-5p/Gal-9 axis drives CD8 (+) T-cell inactivation and is a therapeutic target for hepatocellular carcinoma immunotherapy.
Cancer Lett
; 564: 216186, 2023 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37105392
20.
Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis.
Cell Death Dis
; 14(2): 79, 2023 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36732324